CANCIDAS Drug Patent Profile

When do Cancidas patents expire, and when can generic versions of Cancidas launch?

Cancidas is a drug marketed by Merck and is included in one NDA.

The generic ingredient in CANCIDAS is caspofungin acetate. There are eight drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the caspofungin acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cancidas

A generic version of CANCIDAS was approved as caspofungin acetate by FRESENIUS KABI USA on December 30^th, 2016.

Summary for CANCIDAS

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	67
Clinical Trials:	19
Patent Applications:	2,398
Drug Prices:	Drug price information for CANCIDAS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CANCIDAS
What excipients (inactive ingredients) are in CANCIDAS?	CANCIDAS excipients list
DailyMed Link:	CANCIDAS at DailyMed

See drug prices for CANCIDAS

Recent Clinical Trials for CANCIDAS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cidara Therapeutics Inc.	Phase 3
Cttq	Phase 2
Cidara Therapeutics Inc.	Phase 2

See all CANCIDAS clinical trials

Pharmacology for CANCIDAS

Drug Class

Echinocandin Antifungal

Paragraph IV (Patent) Challenges for CANCIDAS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CANCIDAS	for Injection	caspofungin acetate	50 mg/vial and 70 mg/vial	021227	1	2009-06-26

US Patents and Regulatory Information for CANCIDAS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-001	Jan 26, 2001	AP	RX	Yes	Yes
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-002	Jan 26, 2001	AP	RX	Yes	Yes

Expired US Patents for CANCIDAS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-002	Jan 26, 2001	6,136,783*PED
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-001	Jan 26, 2001	6,136,783*PED
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-002	Jan 26, 2001	5,952,300*PED

International Patents for CANCIDAS

See the table below for patents covering CANCIDAS around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	984860
Australia	706250
Germany	10299013

Supplementary Protection Certificates for CANCIDAS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0620232	08C0036	France		PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416
0620232	2001/029	Ireland		PRODUCT NAME: CASPOFUNGIN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024; PAEDIATRIC INV. PLAN: P/30/2008
0620232	CA 2002 00007	Denmark

CANCIDAS Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Caspofungin (Cancidas)

Introduction

Caspofungin, marketed under the brand name Cancidas, is an echinocandin antifungal agent used primarily for the treatment of invasive fungal infections caused by Candida and Aspergillus species. Here, we delve into the market dynamics and financial trajectory of caspofungin, highlighting key drivers, restraints, and recent developments.

Market Size and Growth

The global caspofungin market was valued at approximately USD 471.57 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 1.9% from 2024 to 2030[1][3][4].

Key Drivers

Increasing Incidence of Fungal Infections

The rising prevalence of candidiasis and other fungal infections, particularly in immunocompromised individuals such as those undergoing chemotherapy or organ transplantation, is a significant driver of the caspofungin market. For instance, the CDC reported that over one-third of people with advanced HIV infection also had oral and throat candidiasis, and there are approximately 1.4 million hospital visits for vaginal candidiasis in the US each year[1].

Advancements in Medical Research and Technology

Ongoing advancements in medical research and technology have enhanced the efficacy and safety profile of caspofungin. Innovations in drug delivery systems and formulation techniques have improved the pharmacokinetics and pharmacodynamics of the drug, making it more effective and safer for patients[3].

Rising Geriatric Population

The expanding elderly population, which is more susceptible to fungal infections, has further driven the demand for caspofungin. This demographic shift is expected to continue contributing to market growth[1][4].

Impact of the COVID-19 Pandemic

Initial Surge in Demand

The COVID-19 pandemic significantly impacted the caspofungin market, particularly during its initial stages. Patients with COVID-19, especially those with underlying hematological conditions, were at a higher risk of developing fungal co-infections. This led to an increased demand for caspofungin as a treatment option for these patients[1][3].

Stabilization Post-Pandemic

However, with the widespread availability of other COVID-19 treatments and the stabilization of healthcare systems, the demand for caspofungin is expected to return to more stable growth rates. Despite this, the pandemic highlighted the importance of antifungal therapies like caspofungin, ensuring continued market growth driven by other factors[1][3].

Market Restraints

Competition from New Therapies

The emergence of new antifungal agents, such as rezafungin, poses a competitive challenge to caspofungin. For example, Cidara Therapeutics and Melinta Therapeutics received FDA approval for rezafungin in March 2023, which could potentially divert market share away from caspofungin[1][3].

Regulatory and Approval Processes

The regulatory environment and the approval process for new drugs can be stringent and time-consuming, which may slow down the introduction of new formulations or indications for caspofungin. This can limit the market's growth potential[3].

Recent Developments

FDA Approvals and Clinical Trials

Recent developments include the FDA approval of rezafungin for the management of candidemia and severe candidiasis, which may influence the market dynamics of caspofungin. Additionally, positive results from the Phase 3 ReSTORE trial of rezafungin conducted by Cidara Therapeutics and Mundipharma have been reported, indicating potential competition in the near future[1][3].

Key Players and Strategic Initiatives

Key players in the caspofungin market, such as Fresenius SE & Co. KGaA, Cipla Inc., Merck & Co., Inc., Sanofi S.A., and others, are engaged in various strategic initiatives including new product launches, partnerships, mergers, and acquisitions. These activities are aimed at bolstering their market presence and staying competitive in the evolving antifungal market[1][3].

Financial Performance

The financial performance of companies involved in the caspofungin market reflects the broader trends in the pharmaceutical industry. For instance, Merck & Co., Inc., one of the key players, reported strong revenue growth in 2022, with worldwide sales of $13.8 billion. However, the specific financial impact of caspofungin on these companies is not as prominently highlighted as other major revenue streams[2].

Regional Market Analysis

North America

North America holds a dominant position in the caspofungin market due to advanced healthcare infrastructure and high awareness of antifungal treatments. This region is expected to continue driving market growth[4].

Asia-Pacific

The Asia-Pacific region is exhibiting the fastest growth rate in the caspofungin market, driven by increasing healthcare spending, growing awareness of fungal infections, and an expanding elderly population[4].

Market Segmentation

By Indication

The candidiasis segment accounts for the largest market share in the caspofungin market. This is due to the high incidence of Candida infections, particularly in immunocompromised patients, and advancements in diagnostic methods that lead to more accurate and timely identification of cases[4].

Conclusion

The caspofungin market is poised for steady growth driven by the increasing incidence of fungal infections, advancements in medical research, and the rising geriatric population. While the COVID-19 pandemic initially boosted demand, the market is expected to stabilize as other treatments become more widely available. Competition from new therapies and regulatory challenges are key restraints, but strategic initiatives by major players are likely to maintain market momentum.

Key Takeaways

• The global caspofungin market is valued at approximately USD 471.57 million in 2023 and is expected to grow at a CAGR of 1.9% from 2024 to 2030.
• Increasing incidence of fungal infections and advancements in medical research are key drivers.
• The COVID-19 pandemic initially surged demand but is expected to stabilize.
• Competition from new therapies and regulatory challenges are significant restraints.
• Key players are engaged in strategic initiatives to maintain market presence.

FAQs

Q: What is the primary use of caspofungin? A: Caspofungin is primarily used for the treatment of invasive fungal infections caused by Candida and Aspergillus species.

Q: How did the COVID-19 pandemic affect the caspofungin market? A: The pandemic initially increased demand for caspofungin due to fungal co-infections in COVID-19 patients, but demand is expected to stabilize as other COVID-19 treatments become more available.

Q: Which region is expected to exhibit the fastest growth in the caspofungin market? A: The Asia-Pacific region is expected to exhibit the fastest growth rate in the caspofungin market.

Q: What are the key drivers of the caspofungin market? A: Key drivers include the increasing incidence of fungal infections, advancements in medical research, and the rising geriatric population.

Q: Who are some of the key players in the caspofungin market? A: Key players include Fresenius SE & Co. KGaA, Cipla Inc., Merck & Co., Inc., Sanofi S.A., and others.

Sources

1. Grand View Research - Caspofungin Market Size, Share And Growth Report, 2030
2. Merck - Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
3. Reanin - Caspofungin Market | Growth | Share | Size | Trends and Forecast
4. Acumen Research and Consulting - Caspofungin Market Size, Share | Forecast 2032